Neurolixis is making strides in developing first-in-class treatments for rare neurological disorders. The lead drug candidate, NLX-112, is Phase 2-ready and has received Orphan Drug designation for treating Spinocerebellar Ataxia. With a proven safety record in over 600 subjects and beneficial motor effects in people with Parkinson’s disease, NLX-112 could be a breakthrough in the movement disorders field.
Additionally, NLX-101 (Phase 1) has Orphan Drug designation for treating Autism Spectrum Disorders: Fragile X syndrome and Rett syndrome, two debilitating neurodevelopmental conditions with high medical need.
Both NLX-112 and NLX-101 have neuroprotective and neuroplastogenic effects, suggesting disease modifying therapeutic activity.
Neurolixis CEO, Adrian Newman-Tancredi, recently presented our rare disease pipeline at the Executive Roundtable organized by WuXi Apptec..

👉 See his 3-minute summary of the Neurolixis program: https://wxpress.wuxiapptec.com/ExecutiveRoundtables.html?id=216